In vivo, in vitro, in silico:
Why computer modelling is the next evolution of the healthcare sector

 

04th September 2018, 15:00-17:00

Room PHS 5B001, European Parliament, Brussels

 

 

15.00 – 15:10

Introduction by Chairs

Lieve Wierinck, Member of the European Parliament (ALDE, Belgium)

15:10 – 15:40

In silico medicine and the Avicenna Alliance: Making Medicine Modern

Thierry Marchal, Secretary General, Avicenna Alliance

Michael Hill, VP Science, Technology and Clinical Affairs, Medtronic

Geena Malhotra, Global Head of Integrated Product Development, Cipla

15:40 – 15:50

V&V40 EU – Verification and Validation in CM&S of Medical Devices

Tina M. Morrison, Deputy Director, Division of Applied Mechanics and Chair of Modeling and Simulation Working Group, FDA

15:50 – 16:15

Feedback and questions from Participants

Dr. Adriano Henney, Chairman of the Board, Avicenna Alliance

16:15 – 16:25

CM&S and medicinal products’ lifecycle

Dr. Ingrid Klingmann, European Forum for Good Clinical Practice

16:25 – 16:50

Feedback and questions from Participants

Dr. Adriano Henney, Chairman of the Board, Avicenna Alliance

16:50 – 17:00

Closing remarks and next steps by Co-Chairs

Lieve Wierinck, Member of the European Parliament (ALDE, Belgium)

17:00 – 18:00

Networking reception and Q&A with speakers

Avicenna Alliance news

Dassault to enhance clinical tech with Medidata acquisition

Dassault Systèmes acquired Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to...

find out more ›

Promote adoption of In Silico Trials through EMA’s strategy on Regulatory Science to 2025

The European Medicine Agency (EMA) has recently published a document that describes its strategy until 2025....

find out more ›

European Strategy for High Performance Computing

On the 17 June, the European Commission published a presentation explaining why they indicated High Performance Computing (HPC) as a priority area for...

find out more ›

Show all activites